Pharmasset, Inc. Company Profile

05:24 EST 26th January 2015 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.

Location

303-A College Road East
Princeton
New Jersey
08540
United States of America

Contact

Phone: (609) 613-4100
Fax: (609) 613-4150
Email: info@pharmasset.com


News Articles [12 Associated News Articles listed on BioPortfolio]

Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Pharmasset, Inc. (Pharmasset.) is a health care pharmaceutical company. The company is engaged in discovering, producing and commercializing medicines to treat viral infections. The company fo...

Tekmira Merges to Create HBV Powerhouse as ex-Pharmasset Geniuses Seek an Encore

Gilead claims victory in Sovaldi arbitration

Gilead Sciences Inc. (NASDAQ:GILD) disclosed in an SEC filing that an arbitration panel ruled Roche (SIX:ROG; OTCQX:RHHBY) failed to establish its claims to Gilead's HCV drug Sovaldi sofosbuvir. Roche...

Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Recently added to the BioPortfolio report store, Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile is a new report from GlobalData published on 2014-11-16. This ...

Costs of New Treatments for Hepatitis C Infection—Reply

In Reply Dr Lopert and Mr Welch and Dr Green make the point that the Gilead purchase of Pharmasset does not accurately reflect the true costs of development of sofosbuvir. We agree.

OnCore performance

Ebb & Flow OnCore performance After helping to develop blockbuster HCV drug Sovaldi sofosbuvir, a team of ex-Pharmasset Inc. executives now have lined up money and assets in OnCore Biopharma Inc. and ...

HBV play OnCore to merge with Tekmira

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) surged $8.98 (57%) to $24.68 on Monday after announcing plans to merge with OnCore Biopharma Inc. (Doylestown, Pa.). Under the proposed merger, OnC...

OnCore adds to HBV pipeline with Enantigen

HBV play OnCore Biopharma Inc. (Doylestown, Pa.) acquired infectious disease company Enantigen Therapeutics Inc. (Doylestown, Pa.) in an all-cash deal of undisclosed size. OnCore gains two HBV program...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Top five promising drugs Phase I (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS Drug Disease Company ARC-520 Hepatitis B virus infection Arrowhead Research GR-MD-02 Non-alcoholic steatohepatitis ...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record